TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15468547

Group type: EXPERIMENTAL
Intervention: Trasylol (T) 6 mln KIU administered from patient's admission to surgery room until skin incision, plus 2 mln KIU from surgical approach to beginning of AC, added to ACA.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Trasylol (T) 3 mln KIU administered similarly to group 1 but not added to ACA.
Number of subjects: 73

Group type: COMPARATOR
Intervention: No Trasylol (T) used.
Number of subjects: 73
Study: 11401884

Group type: EXPERIMENTAL
Intervention: OSLER test after sleep-deprived night
Number of subjects: 10

Group type: COMPARATOR
Intervention: OSLER test after non-sleep-deprived night
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OSLER test
Number of subjects: 10
Study: 9144689

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and epirubicin 60 mg/m2 (Group A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and epirubicin 90 mg/m2 (Group B)
Number of subjects: 68
Study: 8175327

Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional treatment (positive pressure ventilation and supportive care)
Number of subjects: 31
Study: 2885189

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study: 29695226

Group type: EXPERIMENTAL
Intervention: Reminders only
Number of subjects: 196

Group type: COMPARATOR
Intervention: Incentives only
Number of subjects: 196

Group type: COMPARATOR
Intervention: Incentives and reminders
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 196
Study: 28485264

Group type: EXPERIMENTAL
Intervention: 2 g NWT-03
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 5 g NWT-03
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 25472864

Group type: EXPERIMENTAL
Intervention: Isotonic intravenous fluid containing 140 mmol/L of sodium (Na140)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Hypotonic fluid containing 77 mmol/L of sodium (Na77)
Number of subjects: 690
Study: 23744959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.75 mg·kg(‐1) lidocaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.5 mg·kg(‐1) lidocaine
Number of subjects: 90
Study: 20638884

Group type: EXPERIMENTAL
Intervention: New Helicobacter infections
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Chronic Helicobacter infections
Number of subjects: 124

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Helicobacter infections (overall)
Number of subjects: 124
Study: 22073476

Group type: EXPERIMENTAL
Intervention: Lingual orthodontic appliances
Number of subjects: 60

Group type: COMPARATOR
Intervention: Labial orthodontic appliances
Number of subjects: 60
Study: 16316789

Group type: EXPERIMENTAL
Intervention: Buprenorphine (new formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12679775

Group type: EXPERIMENTAL
Intervention: Tenax stent (a‐SiC:H coated)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Nir stent (316L stainless steel)
Number of subjects: 497
Study: 10743863

Group type: EXPERIMENTAL
Intervention: Resorbable citric acid ester softened polylactic acid membranes (RM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non‐resorbable expanded polytetrafluoroethylene (ePTFE) barriers (NRM)
Number of subjects: 29
Study: 8959471

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1490923

Group type: EXPERIMENTAL
Intervention: Amphotericin B mixed with Intralipid (0.7‐1 mg/kg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amphotericin B in 5% dextrose (0.7‐1 mg/kg/day)
Number of subjects: 32
Study: 3899676

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ) 2.5 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alcohol 1 g/kg
Number of subjects: 9
Study: 29774768

Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin (250 mg twice daily for 8 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (250 mg twice daily for 8 weeks)
Number of subjects: 56
Study: 27677810

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study: 24307259

Group type: EXPERIMENTAL
Intervention: Endorsement of the Affordable Care Act (ACA)
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Perception of reimbursement fairness under ACA
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Professional obligation to address societal health policy issues
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Obligation to care for the uninsured or underinsured
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Willingness to accept limits on coverage for expensive drugs and procedures
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Endorsement of ACA by political affiliation
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Endorsement of ACA by compensation type
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Agreement with professional obligations regarding societal health policy
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Belief in obligation to care for uninsured/underinsured
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Agreement with limiting coverage for expensive drugs and procedures
Number of subjects: 3897

Group type: EXPERIMENTAL
Intervention: Endorsement of ACA by specialty
Number of subjects: 3897
Study: 22537843

Group type: EXPERIMENTAL
Intervention: High dexmedetomidine concentration group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low dexmedetomidine concentration group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 120
Study: 20732849

Group type: EXPERIMENTAL
Intervention: Calcipotriol/hydrocortisone combination ointment (calcipotriol 25 mcg/g or 50 mcg/g combined with hydrocortisone 10 mg/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol alone (25 mcg/g or 50 mcg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriol/hydrocortisone combination ointment
Number of subjects: 0
Study: 18172136

Group type: EXPERIMENTAL
Intervention: Community drama ('skits') intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (adults who did not witness the skits)
Number of subjects: 0
Study: 15910620

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12008940

Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 66
Study: 10983060

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy; duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no control intervention mentioned.
Number of subjects: 0
Study: 7551780

Group type: EXPERIMENTAL
Intervention: Peppermint oil mixed with barium preparation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard barium suspension
Number of subjects: 141
Study: 2181841

Group type: EXPERIMENTAL
Intervention: Labetalol (275 +/- 29 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 37351

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure in utero
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure in utero with testicular hypoplasia
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo exposure with testicular hypoplasia
Number of subjects: 308
Study: 31837008

Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (CRT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: No cranial radiotherapy (No CRT)
Number of subjects: 176
Study: 31138136

Group type: EXPERIMENTAL
Intervention: Calcifediol (10 μg per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28540506

Group type: EXPERIMENTAL
Intervention: Continue ALN
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Discontinue ALN
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study: 25759183

Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring (CGM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 23313985

Group type: EXPERIMENTAL
Intervention: Single muscle reinnervation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double muscle reinnervation
Number of subjects: 40
Study: 21600809

Group type: EXPERIMENTAL
Intervention: HPV educational DVD plus health class
Number of subjects: 626

Group type: COMPARATOR
Intervention: Health class only
Number of subjects: 626
Study: 19397534

Group type: EXPERIMENTAL
Intervention: α-adrenoceptor agonists (specifically midodrine)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: midodrine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: etilefrine
Number of subjects: 329
Study: 17388924

Group type: EXPERIMENTAL
Intervention: Rucinol serum 0.3%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 32
Study: 10773855

Group type: EXPERIMENTAL
Intervention: 2.5 mg Linomide
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: 5 mg Linomide
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 8614083

Group type: EXPERIMENTAL
Intervention: Prophylactic vena caval filters (VCFs) placed in 40 patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (NO VCF group) with 80 patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prophylactic vena caval filters (VCFs)
Number of subjects: 120
Study: 1602945

Group type: EXPERIMENTAL
Intervention: Running exercise at 0800, 1200, 1600, and 2000 h (20-min runs at 70% VO2max)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Running exercise at different times of day
Number of subjects: 12
Study: 3970121

Group type: EXPERIMENTAL
Intervention: betaxolol 1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31382171

Group type: EXPERIMENTAL
Intervention: Omega-3-polyunsaturated fatty acids (O3PUFAs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30138017

Group type: EXPERIMENTAL
Intervention: e-mail boosters containing alcohol norms
Number of subjects: 568

Group type: COMPARATOR
Intervention: e-mail boosters containing general health information (control)
Number of subjects: 568
Study: 27687378

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 24385283

Group type: EXPERIMENTAL
Intervention: Intravenous 200 mg gemifloxacin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral 320 mg gemifloxacin
Number of subjects: 17
Study: 22301066

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 608

Group type: COMPARATOR
Intervention: sham/0.5 mg
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 608
Study: 20629022

Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg twice daily (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 34
Study: 18364130

Group type: EXPERIMENTAL
Intervention: Physician transfer group (n=165)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Patient transfer group (n=169)
Number of subjects: 334
Study: 15701909

Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily for 6 months
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (subcutaneous enoxaparin, 1 mg/kg twice daily for 5 to 20 days followed by warfarin)
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2489
Study: 12204728

Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting (Minimal group, n=22)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional open harvesting (Open group, n=18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting (Minimal group)
Number of subjects: 40
Study: 10450299

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 83
Study: 8949696

Group type: EXPERIMENTAL
Intervention: Reflolux II
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 94

Group type: COMPARATOR
Intervention: GOM (Roche Ultimate glucose oxidase method)
Number of subjects: 94
Study: 2019751

Group type: EXPERIMENTAL
Intervention: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine, 100 HID50
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cold-adapted (ca) influenza A/Kawasaki/9/86 reassortant vaccine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine
Number of subjects: 122
Study: 31693564

Group type: EXPERIMENTAL
Intervention: Microdrop blood transfusion set at 10 mL/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macrodrop blood transfusion set at 10 mL/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microdrop blood transfusion set at 100 mL/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macrodrop blood transfusion set at 100 mL/h
Number of subjects: 20
Study: 28162990

Group type: EXPERIMENTAL
Intervention: Psychiatric eConsults (Treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27422584

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) with multicatheter brachytherapy (32.0Gy/8 fractions or 30.1Gy/7 fractions or 50Gy/0.60‐0.80Gy per pulse)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: External Beam Whole Breast Irradiation (WBI) with 50Gy and a boost of 10Gy
Number of subjects: 1186
Study: 24623069

Group type: EXPERIMENTAL
Intervention: Visual inspection of returned empty gel applicators
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Visual assessment of adherence
Number of subjects: 838
Study: 22884754

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 19875477

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 1605
Study: 19208978

Group type: EXPERIMENTAL
Intervention: Screening of all HIV-infected persons for tuberculosis and vice-versa
Number of subjects: 9200000

Group type: EXPERIMENTAL
Intervention: Newer diagnostic tests for TB
Number of subjects: 9200000

Group type: EXPERIMENTAL
Intervention: Treatment of HIV-TB co-infection
Number of subjects: 9200000
Study: 16291408

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 or 2 mg/kg SC weekly for 12 weeks
Number of subjects: 2335

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 2335

Group type: EXPERIMENTAL
Intervention: Efalizumab extended therapy (up to 24 weeks)
Number of subjects: 2335

Group type: EXPERIMENTAL
Intervention: Efalizumab continuous therapy (up to 108 weeks)
Number of subjects: 2335
Study: 12734155

Group type: EXPERIMENTAL
Intervention: s-ketamine 1 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: s-ketamine 2 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: midazolam 0.2 mg.kg(‐1) (Group M)
Number of subjects: 90
Study: 10581142

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 125 mg per hour (total 3 g)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amiodarone after crossover from placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amiodarone vs placebo after 8 h
Number of subjects: 100
Study: 8564104

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) with chest symptoms
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) without chest symptoms
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Negative double-blind, placebo-controlled food challenges (DBPCFC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenges (MIC)
Number of subjects: 26
Study: 1826960

Group type: EXPERIMENTAL
Intervention: Etanidazole (Eta) plus radiotherapy
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control (radiotherapy only)
Number of subjects: 330
Study: 6124473

Group type: EXPERIMENTAL
Intervention: Metronidazole (0.4 g b.i.d.)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sulfasalazine (1.5 g b.i.d.)
Number of subjects: 78
Study: 30522925

Group type: EXPERIMENTAL
Intervention: Venous perfusion assist system (VPAS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Limb elevation
Number of subjects: 102
Study: 28798201

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40
Study: 25239849

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (VD3) supplementation (200,000 IU IM quarterly) and daily oral calcium (Ca) for 12 months (Group D)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 15
Study: 23663206

Group type: EXPERIMENTAL
Intervention: Topical lidocaine/prilocaine
Number of subjects: 15
Study: 21303366

Group type: EXPERIMENTAL
Intervention: Brochure addressing common blood donor concerns and suggesting specific coping strategies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Video addressing blood donor concerns and illustrating coping techniques
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of brochure and video
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 100
Study: 19196529

Group type: EXPERIMENTAL
Intervention: Anamorelin (25 mg daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anamorelin (50 mg daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anamorelin (75 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17002661

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Pre-clopidogrel response to ADP
Number of subjects: 638
Study: 16330592

Group type: EXPERIMENTAL
Intervention: Videotaped interview (testimony method)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 11933550

Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study: 9689700

Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection (TURP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 70
Study: 8154413

Group type: EXPERIMENTAL
Intervention: Metoprolol (M) treatment for 72 hours, supplemented with three intraperitoneal doses over the first 24 hours.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Metoprolol (M) treatment
Number of subjects: 54
Study: 2801447

Group type: EXPERIMENTAL
Intervention: iohexol‐300
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: iopamidol‐300
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: iothalamate‐60
Number of subjects: 75
Study: 1092821

Group type: EXPERIMENTAL
Intervention: Prophylactic cutaneous stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 18
Study: 30840336

Group type: EXPERIMENTAL
Intervention: 1-year gym-based, supervised exercise intervention (150 minutes of aerobic exercise and 2 strength-training sessions each week)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 121
Study: 28052211

Group type: EXPERIMENTAL
Intervention: APF-30 (water rinsing after 30 minutes)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: F-CPP-ACP (using CPP-ACP immediately before water rinsing)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APF-0 (immediate water rinsing)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-F (no fluoride therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CPP-ACP-0 (using CPP-ACP and immediate water rinsing)
Number of subjects: 25
Study: 24627449

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 64
Study: 23172405

Group type: EXPERIMENTAL
Intervention: Supervised by expert (Group A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supervised by expert (Group B)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Order effect of supervision
Number of subjects: 9
Study: 21632808

Group type: EXPERIMENTAL
Intervention: Cotreatment with pegvisomant (15-30 mg twice a week) and SA (half the usual dosage)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SA monotherapy (unchanged dosage)
Number of subjects: 18
Study: 19559191

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) plus aspirin (100 mg) daily
Number of subjects: 197
Study: 16776751

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 314
Study: 15226784

Group type: EXPERIMENTAL
Intervention: L-arginine (9 g/day for 7 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11235692

Group type: EXPERIMENTAL
Intervention: Lower ministernotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100